The Renin-Angiotensin-Aldosterone System (RAAS) is a critical regulator of blood pressure. When we need to lower a patient's blood pressure, interfering with this system is a powerful strategy. The two primary drug classes for this are ACE inhibitors and Angiotensin II Receptor Blockers (ARBs).

ACE inhibitors work by blocking the Angiotensin-Converting Enzyme. This enzyme's job is to convert a relatively inactive peptide, Angiotensin I, into the highly potent vasoconstrictor, Angiotensin II. By inhibiting this step, these drugs reduce the production of Angiotensin II, leading to vasodilation and lower blood pressure.

However, the Angiotensin-Converting Enzyme has another role: it breaks down a substance called bradykinin. When ACE is inhibited, bradykinin levels increase. This accumulation is responsible for the class's most notorious side effect: a persistent, dry cough. In rare cases, it can also cause angioedema, a serious and potentially life-threatening swelling of the deep layers of the skin.

For patients who cannot tolerate the cough from an ACE inhibitor, Angiotensin II Receptor Blockers (ARBs) are an excellent alternative. Instead of preventing the formation of Angiotensin II, ARBs allow it to be produced but block it from binding to its primary target: the AT1 receptor.

By blocking the receptor, ARBs prevent Angiotensin II from causing vasoconstriction and aldosterone release. This achieves the same blood-pressure-lowering effect as ACE inhibitors but through a more targeted mechanism. Crucially, ARBs do not interfere with ACE's ability to break down bradykinin. As a result, they do not cause a cough or carry the same risk of angioedema.

Beyond hypertension, both ACE inhibitors and ARBs have compelling indications for patients with diabetes and chronic kidney disease (CKD). They offer a benefit known as renoprotection, slowing the progression of kidney damage.

This effect is due to their specific action on the glomerulus, the kidney's filtering unit. Angiotensin II preferentially constricts the efferent arteriole (the vessel carrying blood out of the glomerulus) more than the afferent arteriole (the vessel carrying blood in). This creates a 'back-pressure' that increases pressure inside the glomerulus, a state called intraglomerular hypertension. Over time, this high pressure damages the delicate filtering apparatus, leading to proteinuria and a decline in kidney function.

By blocking the effect of Angiotensin II, ACE inhibitors and ARBs cause the efferent arteriole to dilate. This relieves the back-pressure, lowers the intraglomerular pressure, and reduces the strain on the kidneys, thereby preserving their function long-term.

Despite their benefits, these drugs are not for everyone. They are strictly contraindicated in pregnancy as they can cause significant harm to the developing fetus.

Another key contraindication is bilateral renal artery stenosis. In this condition, blood flow to both kidneys is already compromised. These patients rely on Angiotensin II-mediated constriction of the efferent arteriole to maintain enough glomerular pressure for filtration. Blocking this mechanism can lead to a precipitous drop in the glomerular filtration rate (GFR) and cause acute kidney injury.

Understanding these mechanisms allows for precise, effective management of hypertension and related conditions, tailored to individual patient needs and risk factors.